1. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Issue 6 (June 2015) Authors: Mizokami, Masashi; Yokosuka, Osamu; Takehara, Tetsuo; Sakamoto, Naoya; Korenaga, Masaaki; Mochizuki, Hitoshi; Nakane, Kunio; Enomoto, Hirayuki; Ikeda, Fusao; Yanase, Mikio; Toyoda, Hidenori; Genda, Takuya; Umemura, Takeji; Yatsuhashi, Hiroshi; Ide, Tatsuya; Toda, Nobuo; Nirei, Kazushige; Ueno, Yo... Journal: Lancet infectious diseases Issue: Volume 15:Issue 6(2015:Jun.) Page Start: 645 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Issue 4 (April 2015) Authors: Bourlière, Marc; Bronowicki, Jean-Pierre; de Ledinghen, Victor; Hézode, Christophe; Zoulim, Fabien; Mathurin, Philippe; Tran, Albert; Larrey, Dominique G; Ratziu, Vlad; Alric, Laurent; Hyland, Robert H; Jiang, Deyuan; Doehle, Brian; Pang, Phillip S; Symonds, William T; Subramanian, G Mani; McHutc... Journal: Lancet infectious diseases Issue: Volume 15:Issue 4(2015:Apr.) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Issue 4 (April 2015) Authors: Bourlière, Marc; Bronowicki, Jean-Pierre; de Ledinghen, Victor; Hézode, Christophe; Zoulim, Fabien; Mathurin, Philippe; Tran, Albert; Larrey, Dominique G; Ratziu, Vlad; Alric, Laurent; Hyland, Robert H; Jiang, Deyuan; Doehle, Brian; Pang, Phillip S; Symonds, William T; Subramanian, G Mani; McHutc... Journal: Lancet infectious diseases Issue: Volume 15:Issue 4(2015:Apr.) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Issue 9973 (21st March 2015) Authors: Kohli, Anita; Osinusi, Anuoluwapo; Sims, Zayani; Nelson, Amy; Meissner, Eric G; Barrett, Lisa L; Bon, Dimitra; Marti, Miriam M; Silk, Rachel; Kotb, Colleen; Gross, Chloe; Jolley, Tim A; Sidharthan, Sreetha; Petersen, Tess; Townsend, Kerry; Egerson, D'Andrea; Kapoor, Rama; Spurlin, Emily; Sneller,... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Issue 9973 (21st March 2015) Authors: Kohli, Anita; Osinusi, Anuoluwapo; Sims, Zayani; Nelson, Amy; Meissner, Eric G; Barrett, Lisa L; Bon, Dimitra; Marti, Miriam M; Silk, Rachel; Kotb, Colleen; Gross, Chloe; Jolley, Tim A; Sidharthan, Sreetha; Petersen, Tess; Townsend, Kerry; Egerson, D'Andrea; Kapoor, Rama; Spurlin, Emily; Sneller,... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗